Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
aclinical, addressing, administeredintravenously, andtoxicology, andtrial, annum, aproduct, Arizona, ASIA, bortezomib, breadth, breeding, briefly, broker, cardiovascular, carryforward, categorization, categorized, clearance, clinicaltrial, combinationwith, contrast, Corning, creditor, crossing, defense, designfrom, detrimental, deviation, device, dexamethasone, diabetic, dosing, electrical, endedDecember, Enlarged, exert, exit, family, feasibility, fraction, freestanding, FSP, greatest, halt, hierarchy, highest, immunogenicity, incombination, indirect, indirectly, input, insulating, insulation, interrupt, IRB, KAEL, Katharine, Korean, lesion, lowest, lymphoproliferative, man, marketplace, matter, McKinsey, membrane, merger, myelin, myelinated, narrowly, neuronal, neurotrophic, notice, objectionable, obligor, ofthe, orderly, otherintellectual, paragraph, prime, progeny, properly, proximity, pulmonary, radiographic, rationale, recurring, reintroduce, released, renamed, Repayment, residual, Rice, rollforward, Samchully, Scottish, Smithfield, sooner, spinalcord, spine, Spink, stake, step, synthetic, thoracic, trained, transparency, UK, unadjusted, unattractive, underwriting, unfavorable, unobservable, viagen, Watchdog, wire
Removed:
accretion, andbeyond, anemia, antidilutive, approve, ARB, awarded, beneficiary, Centre, cervical, CLA, cleared, CLL, colorectal, commercialscale, concurrently, Consolidation, consummated, controlhuman, conversion, conveyed, cystoscopy, deliveredare, demonstratedin, destroy, discontinued, economically, elevated, engrafted, founder, FSA, glioblastoma, GTI, hepatocellular, improved, infect, infected, intangible, intermittently, invasive, killing, leadership, locally, lymphocytic, lymphoma, lytic, malignant, manipulated, melanoma, Midlothian, narrowing, obligated, oncolytic, ovarian, predictor, prepayment, Pty, radiotherapy, rated, recurrence, refused, reliably, replacement, rigorously, Roche, rupture, satisfy, selective, selectively, succeeded, suggest, Thesein, undergo, unmet, vision, week
Filing tables
Filing exhibits
- 10-K Annual report
- 10.21 Amendment to Employment Agreement Between Registrant and Thomas Okarma
- 10.22 Amendment to Employment Agreement Between Registrant and David Greenwood
- 10.23 Amendment to Employment Agreement Between Registrant and David Earp
- 10.24 Amendment to Employment Agreement Between Registrant and Calvin Harley
- 10.25 Amendment to Employment Agreement Between Registrant and Melissa Kelly Behrs
- 10.26 Amendment to Employment Agreement Between Registrant and Jane Lebkowski
- 10.27 Amended and Restated Severance Plan, Effective December 19, 2008
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer Pursuant to Form of Rule 13A-14(A)
- 31.2 Certification of Chief Financial Officer Pursuant to Form of Rule 13A-14(A)
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350
Related press release
GERN similar filings
Filing view
External links
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Geron Corporation (the “Company”) hereby certifies, to such officer’s knowledge, that:
| (i) | the accompanying annual report on Form 10-K of the Company for the year ended December 31, 2008 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and | ||
| (ii) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. | ||
| Dated: February 27, 2009 | /s/ THOMAS B. OKARMA |
| THOMASB. OKARMA | |
| President and | |
| Chief Executive Officer |
A signed original of this written statement required by Section 906 has been provided to Geron Corporation and will be retained by Geron Corporation and furnished to the Securities and Exchange Commission or its staff upon request.